Skip to main
RANI
RANI logo

RANI Stock Forecast & Price Target

RANI Analyst Ratings

Based on 11 analyst ratings
Strong Buy
Strong Buy 73%
Buy 27%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Rani Therapeutics Holdings Inc. is developing innovative oral delivery technologies that promise to enhance the convenience and compliance of biologic therapies, such as the proprietary RaniPill capsule and RaniPill HC, aimed at replacing painful injections. The company has demonstrated strong preclinical data in canines, suggesting favorable outcomes in human trials, with plans to advance the RT-114 drug into a Phase 2a obesity trial pending successful Phase 1 results. Additionally, Rani's partnerships and ongoing research into multiple obesity programs position the company favorably within a potentially lucrative multi-billion dollar market, indicating a strong outlook for growth and investor interest.

Bears say

Rani Therapeutics Holdings Inc faces significant challenges that contribute to a negative outlook on its stock, primarily due to intense competition in the biotherapeutics market where other companies are developing alternative long-acting injectable formulations. Management turnover poses risks to the continuity and progress of clinical development, potentially delaying key projects and negatively impacting share performance. Furthermore, the company confronts several systemic risks, including the possibility of negative clinical trial results, slow market uptake, and the FDA's stringent approval processes for its innovative RaniPill technology, which could further hinder its overall market penetration and growth potential.

RANI has been analyzed by 11 analysts, with a consensus rating of Strong Buy. 73% of analysts recommend a Strong Buy, 27% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Rani Therapeutics Holdings and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Rani Therapeutics Holdings (RANI) Forecast

Analysts have given RANI a Strong Buy based on their latest research and market trends.

According to 11 analysts, RANI has a Strong Buy consensus rating as of Jun 16, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $13.45, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $13.45, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Rani Therapeutics Holdings (RANI)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.